KR101606495B1 - 올리고뉴클레오타이드 킬레이트 복합체 - Google Patents

올리고뉴클레오타이드 킬레이트 복합체 Download PDF

Info

Publication number
KR101606495B1
KR101606495B1 KR1020137007008A KR20137007008A KR101606495B1 KR 101606495 B1 KR101606495 B1 KR 101606495B1 KR 1020137007008 A KR1020137007008 A KR 1020137007008A KR 20137007008 A KR20137007008 A KR 20137007008A KR 101606495 B1 KR101606495 B1 KR 101606495B1
Authority
KR
South Korea
Prior art keywords
rep
oligonucleotide
chelate complex
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137007008A
Other languages
English (en)
Korean (ko)
Other versions
KR20130099067A (ko
Inventor
앤드류 베일런트
미셀 바지넷
Original Assignee
레플리코르 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45594559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101606495(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 레플리코르 인코포레이티드 filed Critical 레플리코르 인코포레이티드
Publication of KR20130099067A publication Critical patent/KR20130099067A/ko
Application granted granted Critical
Publication of KR101606495B1 publication Critical patent/KR101606495B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
KR1020137007008A 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체 Expired - Fee Related KR101606495B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020157017340A Division KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체
KR20157007582A Division KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체

Publications (2)

Publication Number Publication Date
KR20130099067A KR20130099067A (ko) 2013-09-05
KR101606495B1 true KR101606495B1 (ko) 2016-03-28

Family

ID=45594559

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137007008A Expired - Fee Related KR101606495B1 (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체
KR1020157017340A Withdrawn KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체
KR20157007582A Withdrawn KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157017340A Withdrawn KR20150082685A (ko) 2010-08-20 2011-08-18 올리고뉴클레오티드 킬레이트 복합체
KR20157007582A Withdrawn KR20150039873A (ko) 2010-08-20 2011-08-18 올리고뉴클레오타이드 킬레이트 복합체

Country Status (35)

Country Link
US (2) US8513211B2 (cg-RX-API-DMAC7.html)
EP (1) EP2605794B1 (cg-RX-API-DMAC7.html)
JP (1) JP5775581B2 (cg-RX-API-DMAC7.html)
KR (3) KR101606495B1 (cg-RX-API-DMAC7.html)
CN (2) CN103052405B (cg-RX-API-DMAC7.html)
AU (1) AU2011291401B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003875B1 (cg-RX-API-DMAC7.html)
CA (2) CA2806616C (cg-RX-API-DMAC7.html)
CL (1) CL2013000445A1 (cg-RX-API-DMAC7.html)
CO (1) CO6670525A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130069A (cg-RX-API-DMAC7.html)
CU (1) CU20130022A7 (cg-RX-API-DMAC7.html)
CY (1) CY1118207T1 (cg-RX-API-DMAC7.html)
DK (1) DK2605794T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2013000041A (cg-RX-API-DMAC7.html)
EA (1) EA026660B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012449A (cg-RX-API-DMAC7.html)
ES (1) ES2598556T3 (cg-RX-API-DMAC7.html)
GT (1) GT201300040A (cg-RX-API-DMAC7.html)
HR (1) HRP20161333T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029521T2 (cg-RX-API-DMAC7.html)
IL (1) IL224237A (cg-RX-API-DMAC7.html)
LT (1) LT2605794T (cg-RX-API-DMAC7.html)
MX (1) MX340294B (cg-RX-API-DMAC7.html)
MY (1) MY160961A (cg-RX-API-DMAC7.html)
NZ (1) NZ606364A (cg-RX-API-DMAC7.html)
PH (1) PH12013500192B1 (cg-RX-API-DMAC7.html)
PL (1) PL2605794T3 (cg-RX-API-DMAC7.html)
PT (1) PT2605794T (cg-RX-API-DMAC7.html)
RS (1) RS55245B1 (cg-RX-API-DMAC7.html)
SG (1) SG187165A1 (cg-RX-API-DMAC7.html)
SI (1) SI2605794T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600370B (cg-RX-API-DMAC7.html)
WO (1) WO2012021985A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300497B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
ES2564563T3 (es) 2007-10-26 2016-03-23 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar trastornos del músculo
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
EP4400169A3 (en) 2012-04-23 2024-12-25 Vico Therapeutics B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
TWI635864B (zh) * 2012-05-18 2018-09-21 雷普利可公司 寡核苷酸螯合複合物－多肽組合物及方法
CN110257379B (zh) 2012-07-03 2023-08-11 马林生物科技有限公司 用于治疗肌肉萎缩症患者的寡核苷酸
CN104837501B (zh) * 2012-08-30 2018-11-02 里普利科股份有限公司 治疗乙型肝炎及丁型肝炎感染的方法
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
SMT202000389T1 (it) * 2015-04-23 2020-09-10 Geron Corp Metodi di preparazione di polinucleotidi usando composizioni di sali cationici multivalenti
CN113286803A (zh) * 2018-11-08 2021-08-20 阿里戈斯治疗公司 S-抗原转运抑制寡核苷酸聚合物和方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021198958A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Nucleic acid polymers
AU2021383758A1 (en) * 2020-11-20 2023-06-15 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US20240336921A1 (en) 2021-07-09 2024-10-10 Glaxo Smith Kline Intellectual Property (No. 3) Limited Use of oligonucleotides for individuals with renal impairment
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074041A1 (en) * 1997-08-20 2006-04-06 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3667047B2 (ja) * 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US20070105116A1 (en) * 2003-09-02 2007-05-10 Japan Science And Technology Agency Metal complex type nucleic acid
JP2009500020A (ja) * 2005-07-01 2009-01-08 バイオヴェリス コーポレイション 核酸を検出、増幅および／また単離するための組成物および方法
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074041A1 (en) * 1997-08-20 2006-04-06 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US20060293510A1 (en) * 2003-09-08 2006-12-28 Japan Science And Technology Agency Metal complex type nucleic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Biol Inorg Chem. 2007. Vol.12, pp. 901-911.*
Nucleic Acids Symposium Series. 2008. No.52, pp.485-486.*

Also Published As

Publication number Publication date
PL2605794T3 (pl) 2017-01-31
EP2605794A4 (en) 2014-07-02
HK1184058A1 (zh) 2014-01-17
HUE029521T2 (en) 2017-03-28
CN103052405B (zh) 2015-11-25
PH12013500192A1 (cg-RX-API-DMAC7.html) 2013-03-11
HK1198123A1 (en) 2015-03-13
BR112013003875B1 (pt) 2021-10-05
AU2011291401B2 (en) 2014-11-27
PT2605794T (pt) 2016-10-25
AU2011291401A1 (en) 2013-01-10
CR20130069A (es) 2013-09-20
SMT201600370B (it) 2016-11-10
NZ606364A (en) 2014-12-24
JP2013536195A (ja) 2013-09-19
KR20150039873A (ko) 2015-04-13
SI2605794T1 (sl) 2017-01-31
ECSP13012449A (es) 2013-04-30
CA2855690A1 (en) 2012-02-23
KR20130099067A (ko) 2013-09-05
MX340294B (es) 2016-07-04
CA2806616A1 (en) 2012-02-23
IL224237A (en) 2015-09-24
MX2013001668A (es) 2013-07-22
MY160961A (en) 2017-03-31
EP2605794B1 (en) 2016-07-20
US8716259B2 (en) 2014-05-06
SG187165A1 (en) 2013-02-28
CL2013000445A1 (es) 2013-11-22
ZA201300497B (en) 2013-09-25
KR20150082685A (ko) 2015-07-15
CA2806616C (en) 2015-08-11
LT2605794T (lt) 2016-10-25
EA201300259A1 (ru) 2013-12-30
RS55245B1 (sr) 2017-02-28
JP5775581B2 (ja) 2015-09-09
US20120046348A1 (en) 2012-02-23
CY1118207T1 (el) 2017-06-28
ES2598556T3 (es) 2017-01-27
GT201300040A (es) 2014-09-02
US8513211B2 (en) 2013-08-20
DOP2013000041A (es) 2017-12-15
DK2605794T3 (en) 2016-10-24
CA2855690C (en) 2015-08-25
CN103052405A (zh) 2013-04-17
CO6670525A2 (es) 2013-05-15
HRP20161333T1 (hr) 2016-12-02
CU20130022A7 (es) 2013-04-19
CN103768086B (zh) 2015-10-14
EA026660B1 (ru) 2017-05-31
CN103768086A (zh) 2014-05-07
EP2605794A1 (en) 2013-06-26
US20130296410A1 (en) 2013-11-07
PH12013500192B1 (en) 2018-11-23
BR112013003875A2 (en) 2018-03-13
WO2012021985A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
KR101606495B1 (ko) 올리고뉴클레오타이드 킬레이트 복합체
JP6294308B2 (ja) オリゴヌクレオチドキレート錯体方法
JP2015517504A (ja) オリゴヌクレオチドキレート錯体−ポリペプチド組成物および方法
HK1198123B (en) The use of oligonucleotide chelate complexes
HK1184058B (en) Oligonucleotide chelate complexes

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190307

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240322

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240322